ArticleScientific reports2025
Designing and characterizing first Iranian study evaluating serum levels of lithium in patients for population pharmacokinetics (FIRELOLIPOP): baseline and first report.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bipolar disorder (BD) is a chronic psychiatric illness characterized by recurrent manic and depressive episodes, leading to significant impairment. Lithium remains a key treatment for BD, particularly in relapse prevention. However, its narrow therapeutic range and inter-individual pharmacokinetic variability necessitate careful dosing. This study aims to establish a suitable platform to investigate the pharmacokinetics of lithium in hospitalized patients with BD in Mashhad, Iran, to optimize therapeutic use and minimize toxicity. This cross-sectional study was conducted at Ibn Sina Hospital, Mashhad, between 2016 and 2022. Hospitalized patients diagnosed with BD and receiving lithium therapy were included. Clinical, demographic, and laboratory data were collected, including lithium serum levels, renal function parameters, and co-administered medications. Advanced data pre-processing techniques were applied to ensure accuracy and facilitate future pharmacokinetic modeling. A total of 701 patients (53.1% male, mean age: 38.0 SD: ± 12.2 years) with 795 hospitalization episodes were analyzed. The mean lithium serum concentration was 0.65 ± 0.30 mEq/L. Thyroid disorders (5.9%) and diabetes (5.6%) were the most common comorbidities. The mean duration of hospitalization during lithium treatment was 21.7 ± 10.8 days. Sodium valproate was the most frequently co-prescribed medication (n = 553), followed by lorazepam (n = 468) and risperidone (n = 458). Lithium dosing showed considerable variability, emphasizing the need for individualized therapeutic strategies. This study provides valuable insights into lithium pharmacokinetics in Iranian BD patients. The findings highlight the necessity of personalized dosing approaches to enhance efficacy and reduce adverse effects. Future research should incorporate pharmacokinetic modeling and machine learning to refine lithium therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.